Related Experiment Videos

Changes in GSH-antioxidant system induced by daunorubicin in human normal and diabetic fibroblasts

Agnieszka Zatorska1, Janusz Maszewski, Zofia Jóźwiak

  • 1Department of Thermobiology, University of Łódź, Poland. lgebicka@mitr.p.lodz.pl

Acta Biochimica Polonica
|September 30, 2003
PubMed

Insights

Daunorubicin treatment depletes glutathione (GSH) and alters GSH-related enzyme activity in human fibroblasts. Diabetic cells showed more pronounced effects, indicating daunorubicin disrupts antioxidant defenses.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Pharmacology

Background:

  • Glutathione (GSH) is a critical intracellular antioxidant.
  • Diabetic conditions can impair cellular antioxidant defenses.
  • Daunorubicin is an anticancer drug with potential cellular toxicity.

Purpose of the Study:

  • To investigate the impact of daunorubicin on GSH levels and GSH-related enzyme activity in normal and diabetic human fibroblasts.
  • To compare the cellular response to daunorubicin between normal and diabetic fibroblast models.

Main Methods:

  • Human fibroblasts (normal and diabetic) were exposed to daunorubicin (4 microM) for 2 hours.
  • Cells were subsequently cultured in drug-free medium for up to 72 hours.
  • Intracellular GSH content, GSH ratio, and activities of GSH-related enzymes (peroxidases, glutathione S-transferase, glutathione reductase) were analyzed.

Main Results:

  • Daunorubicin induced a time-dependent decrease in intracellular GSH and the GSH/total glutathione ratio in diabetic fibroblasts.
  • GSH depletion correlated with nuclear apoptotic changes.
  • Activities of Se-dependent/independent peroxidases and glutathione S-transferase increased, while glutathione reductase activity decreased by 50%.
  • Diabetic cells exhibited significant differences in glutathione S-transferase and Se-dependent glutathione peroxidase activities compared to normal cells.

Conclusions:

  • Daunorubicin significantly disrupts the glutathione antioxidant defense system in both normal and diabetic human fibroblasts.
  • Diabetic fibroblasts show altered responses to daunorubicin, suggesting a compromised antioxidant system.
  • These findings highlight the drug's impact on cellular redox balance and potential implications in diabetic patients.

Related Concept Videos